Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
117 hedge funds and large institutions have $1.1B invested in Alder Biopharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 56 increasing their positions, 35 reducing their positions, and 28 closing their positions.
106% more capital inflows, than outflows
Capital inflows: $205M | Capital outflows: $99.4M
60% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 35
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
1.56% less ownership
Funds ownership: 91.72% → 90.15% (-1.6%)
13% less funds holding
Funds holding: 134 → 117 (-17)
50% less call options, than puts
Call options by funds: $7.66M | Put options by funds: $15.5M
54% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$41.7M |
| 2 |
PFM Health Sciences
San Francisco,
California
|
+$38.3M |
| 3 |
Foresite Capital Management III
Larkspur,
California
|
+$24.3M |
| 4 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.1M |
| 5 |
Perceptive Advisors
New York
|
+$8.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$26.1M |
| 2 |
Highbridge Capital Management
New York
|
-$7.15M |
| 3 |
Cadian Capital Management
New York
|
-$7.01M |
| 4 |
BlackRock Advisors
Wilmington,
Delaware
|
-$6.79M |
| 5 |
New Leaf Venture Partners
New York
|
-$5.85M |
ALDR Hedge Fund Activity: Q1 2016 in Review
117 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q1 2016, worth a combined $1.1B — down 17% from $1.33B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ALDR and 13 opened new positions — a net loss of 15 holders — while 35 trimmed existing stakes and 56 added.
The largest buyer was Wellington Management Group, adding an estimated $41.7M. The largest seller was Millennium Management, exiting entirely with an estimated $26.1M sold.
- 117 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q1 2016, down from 134 in Q4 2015.
- Funds reported $1.1B of Alder Biopharmaceuticals stock for Q1 2016, down 17% quarter-over-quarter.
- 13 funds opened new Alder Biopharmaceuticals positions in Q1 2016 and 28 closed out, a net change of -15 holders.
- The largest Alder Biopharmaceuticals buyer in Q1 2016 was Wellington Management Group, an estimated $41.7M added.
- The largest Alder Biopharmaceuticals seller in Q1 2016 was Millennium Management, an estimated $26.1M sold.
Based on aggregated 13F filings for Q1 2016.